250 related articles for article (PubMed ID: 25809837)
1. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
Sunde B; Ericson J; Kumagai K; Lundell L; Tsai JA; Lindblad M; Rouvelas I; Friesland S; Wang N; Nilsson M
Dis Esophagus; 2016 Jul; 29(5):442-7. PubMed ID: 25809837
[TBL] [Abstract][Full Text] [Related]
2. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Pellen MG; Sabri S; Razack A; Gilani SQ; Jain PK
Dis Esophagus; 2012 Jan; 25(1):48-53. PubMed ID: 21595778
[TBL] [Abstract][Full Text] [Related]
5. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Lund M; Alexandersson von Döbeln G; Nilsson M; Winter R; Lundell L; Tsai JA; Kalman S
Radiat Oncol; 2015 Jan; 10():16. PubMed ID: 25582305
[TBL] [Abstract][Full Text] [Related]
6. Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial.
Sunde B; Johnsen G; Jacobsen AB; Glenjen NI; Friesland S; Lindblad M; Rouvelas I; Wang N; Lundell L; Lagergren P; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30084992
[TBL] [Abstract][Full Text] [Related]
7. Self-Expanding Metal Stents Improve Swallowing and Maintain Nutrition During Neoadjuvant Therapy for Esophageal Cancer.
Smith ZL; Gonzaga JE; Haasler GB; Gore EM; Dua KS
Dig Dis Sci; 2017 Jun; 62(6):1647-1656. PubMed ID: 28391413
[TBL] [Abstract][Full Text] [Related]
8. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
[TBL] [Abstract][Full Text] [Related]
10. Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Thukral A; Metz J; Hwang WT; O'Dwyer P; Plastaras J; Both S; Bar-Ad V
Dis Esophagus; 2011 Jul; 24(5):330-6. PubMed ID: 21143694
[TBL] [Abstract][Full Text] [Related]
11. Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction.
Strandby RB; Svendsen LB; Bæksgaard L; Egeland C; Achiam MP
Scand J Surg; 2016 Jun; 105(2):97-103. PubMed ID: 26250355
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
14. Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy.
Siddiqui AA; Sarkar A; Beltz S; Lewis J; Loren D; Kowalski T; Fang J; Hilden K; Adler DG
Gastrointest Endosc; 2012 Jul; 76(1):44-51. PubMed ID: 22726465
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Touchefeu Y; Archambeaud I; Landi B; Lièvre A; Lepère C; Rougier P; Mitry E
Dig Liver Dis; 2014 Mar; 46(3):283-6. PubMed ID: 24268567
[TBL] [Abstract][Full Text] [Related]
16. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
Kawamoto T; Nihei K; Sasai K; Karasawa K
Int J Clin Oncol; 2018 Dec; 23(6):1076-1083. PubMed ID: 30066207
[TBL] [Abstract][Full Text] [Related]
17. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
Penniment MG; De Ieso PB; Harvey JA; Stephens S; Au HJ; O'Callaghan CJ; Kneebone A; Ngan SY; Ward IG; Roy R; Smith JG; Nijjar T; Biagi JJ; Mulroy LA; Wong R;
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):114-124. PubMed ID: 29248399
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
19. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
20. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
